China NMPA Drug Inspection - Sichuan Pharmaceutical Co., Ltd. - Arrowroot

The Sichuan Provincial Food and Drug Administration issued a Drug Quality Bulletin on September 13, 2018, announcing findings from supervisory sampling inspections conducted across the province. These inspections aimed to enhance drug supervision and ensure public safety.

The bulletin disclosed that 21 batches of drugs were found to be substandard. The violations, identified across various manufacturers and product types including granules, capsules, and traditional Chinese medicine slices, primarily involved quality control deficiencies. Common issues included discrepancies in fill weight or quantity, unacceptable appearance, impurities, non-compliance with specific physical properties, and inaccurate content determination of active ingredients. Examples of affected companies include Guilin Ge Xian Weng Pharmaceutical Co., Ltd., Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd., and Tonghua Wantong Pharmaceutical Co., Ltd., among others.

These inspections were conducted in accordance with the National Drug Sampling Management Measures and specific provincial requirements, referencing standards such as the Chinese Pharmacopoeia. In response to these findings, the Provincial Bureau mandated that municipal food and drug administrations investigate and address the illegal activities of the implicated production, sales, and usage units. Local authorities are required to publicize their handling results within three months and report back to the Provincial Bureau, ensuring accountability and adherence to drug administration laws and regulations.